Investor Eye: Juno Capital Believes Medtech Is An Optimal Long-Term Investment
Executive Summary
Juno Capital partner Edward Rudd believes that investing in medtech offers not only a long-term strategy for allocating capital, but an altruistic relief for investors.
You may also be interested in...
Minute Insight: FDA Clears Sky Medical’s Latest Blood Flow-Boosting Geko Device
The Geko W3 is a wearable device that increases blood flow to treat venous insufficiency and/or ischaemia.
Minute Insight: Olympus Corporation Joins VC Race With Its Own Fund
The Japanese company is hoping to access breaking technologies sooner via earlier investment.
Getting A Head Start: Medtech VC Aims Earlier Than Ever Before
As the value of medtech deals increases, investors are increasingly looking for earlier opportunities. COVID-19 has added both impetus and new opportunity, with innovators and investors vying to build a position in digital health technologies, such as remote monitoring and digital therapeutics.